La Roche-Posay is aiming to hit €3bn in sales this year as part of its strategy to become the go-to dermo-cosmetics brand for beauty lovers.
In its 50th anniversary year, the L’Oréal Groupe-owned label plans to achieve this goal by doubling down on its four core principles (Prescription, Pioneering, Patient, Purpose) and educating Gen Z holistically on acne management, while also investing in greater innovations and renovations in its hero ranges.
Neuroscience will be a key area of interest going forward, while expansion into microbiome science and scar management will also be part of the company’s future growth strategy.
And it seems the world’s most prescribed dermatological beauty brand is in a good position to deliver big numbers this year, having achieved €2.9bn net sales in 2024, with Cicaplast Baume B5+ Repairing Balm and recent franchise Mela B3 behind this performance.
La Roche-Posay was also cited in L’Oréal’s recent financial results as the number one growth contributor to its Dermatological Beauty Division [which the brand sits within], helping it to grow +2.7% like-for-like to €2.1bn net sales in Q1 2025.
We are always trying to be ahead of our time and I think that is very important
“It took us 30 years to get to the first billion [annual sales mark], and then two years to reach the second billion [annual sales mark], so now we are trying to hit the third billion [annual sales mark] this year, that's the target,” Alexandra Reni-Catherine, Global Brand General Manager at La Roche-Posay, told Cosmetics Business.
“The success recipe of La Roche-Posay is our business model – that very healthy connection to doctors and understanding their needs, and also taking insight from doctors to build products that are very different from other brands.
“More than 100,000 dermatologists across the world prescribe us on a daily basis, and that is the beginning of everything, because that is where we build trust.
“We are first and foremost a medical brand and that is really the core of who we are – we are patient-centric.
“And doing our [four principles] at the same time is why we have been able to connect so well [with consumers] over the past year, and the market has been in our favour post-Covid-19, where drugstores have been the new place to buy beauty.”
More than 100,000 dermatologists worldwide prescribe La Roche-Posay
A slow and steady approach
Leaning into its pioneering, patient-centric nature will be at the forefront of La Roche-Posay’s forecasted growth for the brand in 2025 and beyond, especially in terms of new research into the fields of neuroscience, microbiome science and further molecular innovation.
“We are always trying to be ahead of our time and I think that is very important,” says Reni-Catherine.
“However, when you look at other brands, we do not have the same pace of innovation because ours are based on
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.
Subscribe now Already a subscriber? Sign in here.